Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biocryst Pharmaceuticals Inc (BCRX) -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (112)	3/27/2007 7:39:10 PM
From: biofisher	Respond to of 269

Is that an odd way to characterize vial cap contamination, or is there more to the story than the vial caps? Wrong way. No mention of anything other than ingredient/cap interaction on conference call. I bought a bit more too.

To: tom pope who wrote (112)	3/28/2007 1:06:57 PM
From: Doc Bones	Respond to of 269

This is from BCRX's own press release: BIRMINGHAM, Ala., March 27 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX - News) today provided an update regarding the company's development programs for Fodosine(TM). Phase IIb Trial in T-ALL Voluntarily Placed on Hold by BioCryst Due to Stability Issue with the Intravenous Formulation of Fodosine(TM) [snip] biz.yahoo.com It's not odd - this result came from 'stability tests', even if the vile vial stopper was the sole cause. Doc